Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study

CONCLUSION: In patients with heavily pretreated advanced HR+/HER2- BC and TNBC, Dato-DXd demonstrated promising clinical activity and a manageable safety profile. Dato-DXd is currently being evaluated in phase III studies.PMID:38652877 | DOI:10.1200/JCO.23.01909

Source: Clinical Breast Cancer - April 23, 2024 Category: Cancer & Oncology Authors: Aditya Bardia Ian E Krop Takahiro Kogawa Dejan Juric Anthony W Tolcher Erika P Hamilton Toru Mukohara Aaron Lisberg Toshio Shimizu Alexander I Spira Junji Tsurutani Senthil Damodaran Kyriakos P Papadopoulos Jonathan Greenberg Fumiaki Kobayashi Hong Zebger Source Type: research